Incannex Healthcare (IXHL) Income from Continuing Operations (2022 - 2026)
Incannex Healthcare (IXHL) posted quarterly Income from Continuing Operations of 3883000.0 for Q1 2026, up 2.14% year-on-year from 3801565.26 in Q1 2025, and up 40.45% on a QoQ basis from 6521000.0 in Q4 2025.
Incannex Healthcare (IXHL) Income from Continuing Operations (2022 - 2026) Analysis & Trends
Incannex Healthcare (IXHL) has reported Income from Continuing Operations for 5 consecutive years, with 3883000.0 the latest figure, recorded in Q1 2026.
- Quarterly Income from Continuing Operations rose 2.14% year-over-year to 3883000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 48414000.0 (down 122.97% YoY) and the FY2025 annual result came in at 46885000.0, down 154.0% from the prior year.
- Income from Continuing Operations rose to 3883000.0 in Q1 2026 per IXHL's latest filing, from 6521000.0 in the prior quarter.
- Over the last five years, Income from Continuing Operations for IXHL reached as high as 726000.0 in Q3 2023 and fell as low as 31603000.0 in Q2 2025.
- A 5-year average of 6627714.29 and a median of 5330500.0 in 2023 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2024 — Income from Continuing Operations slumped 646.56% — and 2025, when it soared 34.21%.
- Year by year, Income from Continuing Operations stood at 2918000.0 in 2022, then tumbled by 79.61% to 5241000.0 in 2023, then declined by 12.46% to 5894000.0 in 2024, then retreated by 10.64% to 6521000.0 in 2025, then surged by 40.45% to 3883000.0 in 2026.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 3883000.0, 6521000.0, and 6407000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 370.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 601.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -3.58 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 274.90 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 176.40 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 197.90 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 57.00 Mn |
| 10 | Incannex Healthcare | 3.63 Mn | 3.63 Mn | - | -3.88 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3.88 Mn |
| Dec 31, 2025 | -6.52 Mn |
| Sep 30, 2025 | -6.41 Mn |
| Jun 30, 2025 | -31.60 Mn |
| Mar 31, 2025 | -3.97 Mn |
| Dec 31, 2024 | -5.89 Mn |
| Sep 30, 2024 | -5.42 Mn |
| Jun 30, 2024 | -6.43 Mn |
| Mar 31, 2024 | -6.03 Mn |
| Dec 31, 2023 | -5.24 Mn |
| Sep 30, 2023 | -726,000.00 |
| Jun 30, 2023 | -4.17 Mn |
| Mar 31, 2023 | -3.57 Mn |
| Dec 31, 2022 | -2.92 Mn |